NEW YORK CITY, NEW YORK / ACCESSWIRE / November 20, 2018 / CEO of Co-Diagnostics Inc, (Nasdaq: CODX) a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, recently sat down with Wall Street Club TV to discuss direction of the company, its technology, and entry into new verticals.
The interview covers a range of topics, including:
- Explanation of recent CEO comments discussing the importance of the LGC, Biosearch license agreement for the Company's technology, and its near- and long-term impact on the Company;
- Momentum being built by recent advancements in the company's patented intellectual property and regulatory clearance, which the Company expects to parlay into increased sales and entry into the new verticals of liquid biopsy and agriculture; and
- The importance of the Company's new website in telling their story and showcasing the expanded applications of the Company's patented technology in multiplexing, SNP detection, next gen sequencing, and more.
Video and transcript of the interview is set to be released by Wall Street Club on November 27, 2018
About The Wall Street Club:
The Wall Street Club (WSC) is a financial digital media company whose focus is to provide readers with news and content on the latest trends and happenings in the financial industry. WSC accepts sole responsibility for the content and distribution of the foregoing release.
Disclaimer
The Wall Street Club (WSC) does not hold any position in the company covered within the article. The information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained in this analysis reflect our current judgement and are subject to change without notice. We do not accept any responsibility or liability for any losses, damages or costs arising from an investor's or other person's reliance on or use of this analysis. This analysis is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities, nor a recommendation of any security. Past gains are not a representative of future gains. The opinions herein contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. When used herein, the words "anticipate," "intend," "estimate," "believe," "expect," "plans," "should," "potential," "forecast," and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A company's actual results could differ materially from those described in any forward-looking statements contained herein. The Wall Street Club is not a licensed broker, broker dealer, market maker, investment advisor, analyst or underwriter. We recommend that you use the information found herein as an initial starting point for conducting your own research in order to determine your own personal opinion of the companies discussed herein before deciding whether or not to invest. You should seek such investment, tax, financial, accounting or legal advice appropriate for your particular circumstances. Information about many publicly traded companies and other investor resources can be found at www.sec.gov. Investing in securities is speculative and carries risk.
Press Contact:
The Wall Street Club
SOURCE: Co-Diagnostics, Inc.
View source version on accesswire.com:
https://www.accesswire.com/528572/Co-Diagnostics-CEO-Records-Exclusive-Interview-Discussing-Progress-Momentum-and-Future-Ambitions
